Atopik Dermatit ve Genetik

Arga, Mustafa

doi:10.21911/aai.359

Cited by 1 publication

(18 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All questions except for demographic ones were prepared in line with national and international guideline recommendations. [4][5][6][7] The questionnaire particularly investigated which generation of AHs they preferred in AU treatment, their sCS administration recommendations, and their administration route preferences for these treatments (oral, intramuscular [i.m. ], intravenous [i.v.]).…”

Section: Methodsmentioning

confidence: 99%

“…13 Because of their abovementioned features, current urticaria guidelines recommend quadrupling the recommended dose in urticaria patients as second-line treatment, if clinical response cannot be obtained at initial routinely administered dose. [4][5][6][7] On the other hand, 1st-GAHs are lipophilic drugs that can easily cross the blood-brain barrier, have weak specificity, and low molecular weight; therefore, they suppress the central nervous system and cause significant sedation and cognitive function impairment. 17 Many side effects associated with 1st-GAHs that affect daily life have been reported, such as impaired REM sleep and reduced school success.…”

Section: Pediatricians' Adherence To Urticaria Guideline Recommendati...mentioning

confidence: 99%

“…2 All current national and international urticaria guidelines recommend the use of second generation H 1 AHs (2nd-GAHs) as the first choice. [4][5][6][7][8][9] Moreover, systemic corticosteroid (sCS) usage is not recommended for all patients. [4][5][6][7] In clinical practice, pediatricians may prefer first generation H 1 AHs (1st-GAHs), the use of which as first choice is absolutely not recommended by urticaria guidelines.…”

mentioning

confidence: 99%

“…[4][5][6][7][8][9] Moreover, systemic corticosteroid (sCS) usage is not recommended for all patients. [4][5][6][7] In clinical practice, pediatricians may prefer first generation H 1 AHs (1st-GAHs), the use of which as first choice is absolutely not recommended by urticaria guidelines. 3 Today, a considerable number of urticaria patients in our country are administered pheniramine maleate (Avil) and dexamethasone (Dekort) by physicians in emergency departments (EDs) as a ritual/traditional treatment.…”

mentioning

confidence: 99%

“…In fact, these treatment approaches may lead to the development of serious side effects in children. [4][5][6][7] Clinical practice guidelines (CPGs) are systematically developed statements that are intended to provide assistance to physicians and patients in deciding which management option is appropriate in specific situations. Clinical practice guidelines enhance the quality of medical decisions made during treatment, and contribute considerably to the improvement of health outcomes by promoting the use of proven and effective treatments and encouraging the avoidance of ineffective treatments.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Do Pediatric Emergency Physicians Comply With Guideline Recommendations in Management of Patients With Acute Urticaria?

Yiğit

Cavkaytar²,

Besli

et al. 2021

Pediatr Emer Care

View full text Add to dashboard Cite

Objectives: To determine the level of knowledge and practical preferences of pediatricians regarding acute urticaria (AU) management and to assess the effects of training provided in accordance with the current urticaria guideline recommendations on pediatricians who work in the pediatric emergency department (PED).Methods: A theoretical training was provided to pediatricians regarding the diagnosis and treatment of AU in line with current urticaria guideline recommendations. Before the training, pediatricians completed a 10-item questionnaire. This prospective study assesses their treatment approaches in patients admitted to PED because of AU during the 6-month period before and the 1-year period after training.Results: Four hundred seventeen children in the pretraining and 1085 children in the posttraining periods were treated for AU in PED. Forty-eight pediatricians participated in the training. According to their questionnaire responses, 35% of them used only H 1 antihistamine (AH) treatment, 50% used second-generation H 1 AH (2nd-GAH) as AHs, 75% preferred the oral route of administration, and 85.4% did not administer systemic corticosteroid (sCS) to all patients. Comparing the practice approaches of the pediatricians in the pretraining and posttraining periods, first-generation H 1 antihistamine (1st-GAH) preference rate decreased from 68.4% to 30.3% and the sCS preference rate decreased from 58.5% to 25.7%, while the 2nd-GAH preference rate increased from 31.7% to 69.7% (P < 0.001 for all). No treatments were prescribed for 10.8% of patients before the training and 3% after the training during discharge at home (P < 0.05). Comparing the home treatment choices of the pediatricians in the pretraining and posttraining periods, 1 st -GAH preference rate decreased from 11.5% to 5%, while the 2 nd -GAH preference rate increased from 78.7% to 91.5% (for both parameters, P < 0.001).Conclusions: Practical treatment preferences of pediatricians in the treatment of children with AU differ considerably from both current guideline recommendations and their own theoretical knowledge, and training can enhance pediatricians' compliance with current guideline recommendations.

show abstract

Section: Methodsmentioning

confidence: 99%